These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

642 related items for PubMed ID: 14506186

  • 1. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG, Oosterwijk E, Soede AC, Oyen WJ, McBride WJ, Griffiths GL, Goldenberg DM, Corstens FH, Boerman OC.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [Abstract] [Full Text] [Related]

  • 2. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG, Oosterwijk E, Soede AC, Broekema M, Frielink C, McBride WJ, Goldenberg DM, Corstens FH, Boerman OC.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [Abstract] [Full Text] [Related]

  • 3. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
    van Schaijk FG, Broekema M, Oosterwijk E, van Eerd JE, McBride BJ, Goldenberg DM, Corstens FH, Boerman OC.
    J Nucl Med; 2005 Jun 01; 46(6):1016-22. PubMed ID: 15937314
    [Abstract] [Full Text] [Related]

  • 4. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG, Oosterwijk E, Molkenboer-Kuenen JD, Soede AC, McBride BJ, Goldenberg DM, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2005 Mar 01; 46(3):495-501. PubMed ID: 15750164
    [Abstract] [Full Text] [Related]

  • 5. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM, Karacay H, Richel H, McBride WJ, Rossi EA, Chang K, Yeldell D, Griffiths GL, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [Abstract] [Full Text] [Related]

  • 6. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
    Cardillo TM, Karacay H, Goldenberg DM, Yeldell D, Chang CH, Modrak DE, Sharkey RM, Gold DV.
    Clin Cancer Res; 2004 May 15; 10(10):3552-61. PubMed ID: 15161715
    [Abstract] [Full Text] [Related]

  • 7. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate.
    Boerman OC, Kranenborg MH, Oosterwijk E, Griffiths GL, McBride WJ, Oyen WJ, de Weijert M, Oosterwijk-Wakka J, Hansen HJ, Corstens FH.
    Cancer Res; 1999 Sep 01; 59(17):4400-5. PubMed ID: 10485489
    [Abstract] [Full Text] [Related]

  • 8. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2004 Feb 01; 45(2):327-37. PubMed ID: 14960657
    [Abstract] [Full Text] [Related]

  • 9. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
    Gold DV, Goldenberg DM, Karacay H, Rossi EA, Chang CH, Cardillo TM, McBride WJ, Sharkey RM.
    Cancer Res; 2008 Jun 15; 68(12):4819-26. PubMed ID: 18559529
    [Abstract] [Full Text] [Related]

  • 10. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.
    Karacay H, McBride WJ, Griffiths GL, Sharkey RM, Barbet J, Hansen HJ, Goldenberg DM.
    Bioconjug Chem; 2000 Jun 15; 11(6):842-54. PubMed ID: 11087333
    [Abstract] [Full Text] [Related]

  • 11. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E, Le Doussal JM, Bouhou J, Manetti C, Martin M, Rouvier E, Barbet J.
    J Nucl Med; 1998 Nov 15; 39(11):1937-43. PubMed ID: 9829586
    [Abstract] [Full Text] [Related]

  • 12. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ, Rogers BE, Khazaeli MB, Mayo MS, Milenic DE, Kashmiri SV, Anderson CJ, Chappell LL, Brechbiel MW, Curiel DT.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [Abstract] [Full Text] [Related]

  • 13. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
    Moosmayer D, Berndorff D, Chang CH, Sharkey RM, Rother A, Borkowski S, Rossi EA, McBride WJ, Cardillo TM, Goldenberg DM, Dinkelborg LM.
    Clin Cancer Res; 2006 Sep 15; 12(18):5587-95. PubMed ID: 17000696
    [Abstract] [Full Text] [Related]

  • 14. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boerman OC.
    J Nucl Med; 2004 Jul 15; 45(7):1224-32. PubMed ID: 15235070
    [Abstract] [Full Text] [Related]

  • 15. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E, Rouvier E, Daniel L, Loucif E, Bouhou J, Manetti C, Martin M, Le Doussal JM, Barbet J.
    J Nucl Med; 2000 Mar 15; 41(3):480-7. PubMed ID: 10716323
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
    Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, Resche I, Devillers A, Laffont S, Bardiès M, Chang K, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
    [Abstract] [Full Text] [Related]

  • 17. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
    Su FM, Beaumier P, Axworthy D, Atcher R, Fritzberg A.
    Nucl Med Biol; 2005 Oct 01; 32(7):741-7. PubMed ID: 16243650
    [Abstract] [Full Text] [Related]

  • 18. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
    Safavy A, Khazaeli MB, Safavy K, Mayo MS, Buchsbaum DJ.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
    [Abstract] [Full Text] [Related]

  • 19. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy.
    Rossi EA, Sharkey RM, McBride W, Karacay H, Zeng L, Hansen HJ, Goldenberg DM, Chang CH.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3886S-96S. PubMed ID: 14506187
    [Abstract] [Full Text] [Related]

  • 20. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
    Müller C, Schubiger PA, Schibli R.
    Nucl Med Biol; 2007 Aug 01; 34(6):595-601. PubMed ID: 17707798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.